CompletedNCT05164549
Comparing long-acting medicines for opioid recovery care
About this title
Extended-release Pharmacotherapy for Opioid Use Disorder
Read the official source — NCT05164549Medication studyAges 18+United KingdomAddiction
Understand this study
Who was this study for?
Listed age limits: from 18 years.
- Listed locations
- Birmingham and 4 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateStarted: August 6, 2019
- Recruitment status
- Completed
- Enrollment listed in the registry
- 342
- Sponsor
- King's College London
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United Kingdom
- Age range
- Over 18 Years
- Official registry ID
- NCT05164549
- Official title
Show the full official title
Extended-release Pharmacotherapy for Opioid Use Disorder (EXPO): Protocol for an Open-label Randomised Controlled Trial of Injectable Maintenance Buprenorphine With Personalised Psychosocial Intervention.
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Birmingham · Dundee · London
2 more locations
- Manchester
- Newcastle upon Tyne
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is King's College London, a university.
Did this study involve medication?
Yes. The study involved medication, including Buprenorphine Injectable Product, Methadone and Buprenorphine.
Who was this study for?
Listed age limits: from 18 years.
